Portola raises $60 million
This article was originally published in Scrip
Executive Summary
Portola Pharmaceuticals, a private US biotechnology company, has raised $60 million. The proceeds will be used to advance Portola's two lead antithrombotic clinical candidates, betrixaban (formerly PRT054021) and PRT060128, and to develop the company's preclinical pipeline including a Factor Xa inhibitor antidote.